BIOMAT Database Logo BIOMAT Database Logo

Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis. 2014

Sonya J Snedecor, and Lavanya Sudharshan, and Katherine Nedrow, and Abhijeet Bhanegaonkar, and Kit N Simpson, and Seema Haider, and Richard Chambers, and Charles Craig, and Jennifer Stephens
1 Pharmerit International , Bethesda, Maryland.

The prevalence of HIV drug resistance varies with geographic location, year, and treatment exposure. This study generated yearly estimates of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in treatment-naive (TN) and treatment-experienced (TE) patients in the United States (US), Europe (EU), and Canada. Studies reporting NNRTI resistance identified in electronic databases and 11 conferences were analyzed in three groups: (1) TN patients in one of four geographic regions [US, Canada, EU countries with larger surveillance networks ("EU1"), and EU countries with fewer data ("EU2")]; (2) TE patients from any region; and (3) TN patients failing NNRTI-based treatments in clinical trials. Analysis data included 158 unique studies from 22 countries representing 84 cohorts of TN patients, 21 cohorts of TE patients, and 8 trials reporting resistance at failure. From 1995 to 2000, resistance prevalence in TN patients increased in US and EU1 from 3.1% to 7.5% and 0.8% to 3.6%, respectively. Resistance in both regions stabilized in 2006 onward. Little resistance was identified in EU2 before 2000, and increased from 2006 (5.0%) to 2010 (13.7%). One TN Canadian study was identified and reported resistance of 8.1% in 2006. Half of TN clinical trial patients had resistance after treatment failure at weeks 48-144. Resistance in TE patients increased from 1998 (10.1%) to 2001 (44.0%), then decreased after 2004. Trends in NNRTI resistance among TN patients show an increased burden in the US and some EU countries compared to others. These findings signify a need for alternate first-line treatments in some regions.

UI MeSH Term Description Entries
D002170 Canada The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.
D005060 Europe The continent north of AFRICA, west of ASIA and east of the ATLANTIC OCEAN. Northern Europe,Southern Europe,Western Europe
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences
D017211 Treatment Failure A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series. Failure, Treatment,Failures, Treatment,Treatment Failures
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse

Related Publications

Sonya J Snedecor, and Lavanya Sudharshan, and Katherine Nedrow, and Abhijeet Bhanegaonkar, and Kit N Simpson, and Seema Haider, and Richard Chambers, and Charles Craig, and Jennifer Stephens
Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: a phase 1 study.
December 2004, The Journal of infectious diseases,
Sonya J Snedecor, and Lavanya Sudharshan, and Katherine Nedrow, and Abhijeet Bhanegaonkar, and Kit N Simpson, and Seema Haider, and Richard Chambers, and Charles Craig, and Jennifer Stephens
High nonnucleoside reverse transcriptase inhibitor resistance levels in HIV-1-infected Zambian mother-infant pairs.
October 2020, AIDS (London, England),
Sonya J Snedecor, and Lavanya Sudharshan, and Katherine Nedrow, and Abhijeet Bhanegaonkar, and Kit N Simpson, and Seema Haider, and Richard Chambers, and Charles Craig, and Jennifer Stephens
Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase.
August 2019, Antimicrobial agents and chemotherapy,
Sonya J Snedecor, and Lavanya Sudharshan, and Katherine Nedrow, and Abhijeet Bhanegaonkar, and Kit N Simpson, and Seema Haider, and Richard Chambers, and Charles Craig, and Jennifer Stephens
HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors.
January 1996, Biochemistry,
Sonya J Snedecor, and Lavanya Sudharshan, and Katherine Nedrow, and Abhijeet Bhanegaonkar, and Kit N Simpson, and Seema Haider, and Richard Chambers, and Charles Craig, and Jennifer Stephens
Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.
October 2004, Current HIV research,
Sonya J Snedecor, and Lavanya Sudharshan, and Katherine Nedrow, and Abhijeet Bhanegaonkar, and Kit N Simpson, and Seema Haider, and Richard Chambers, and Charles Craig, and Jennifer Stephens
Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.
April 2011, Antimicrobial agents and chemotherapy,
Sonya J Snedecor, and Lavanya Sudharshan, and Katherine Nedrow, and Abhijeet Bhanegaonkar, and Kit N Simpson, and Seema Haider, and Richard Chambers, and Charles Craig, and Jennifer Stephens
CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.
October 2010, Therapeutic drug monitoring,
Sonya J Snedecor, and Lavanya Sudharshan, and Katherine Nedrow, and Abhijeet Bhanegaonkar, and Kit N Simpson, and Seema Haider, and Richard Chambers, and Charles Craig, and Jennifer Stephens
Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor.
December 1990, Science (New York, N.Y.),
Sonya J Snedecor, and Lavanya Sudharshan, and Katherine Nedrow, and Abhijeet Bhanegaonkar, and Kit N Simpson, and Seema Haider, and Richard Chambers, and Charles Craig, and Jennifer Stephens
Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.
January 2002, HIV clinical trials,
Sonya J Snedecor, and Lavanya Sudharshan, and Katherine Nedrow, and Abhijeet Bhanegaonkar, and Kit N Simpson, and Seema Haider, and Richard Chambers, and Charles Craig, and Jennifer Stephens
Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women.
December 2004, Journal of acquired immune deficiency syndromes (1999),
Copied contents to your clipboard!